Organon & Co (NYSE: OGN) — Company Overview, News & Financial Data
Organon & Co is a healthcare company focused on women's health, developing tailored therapies and biosimilars globally.
Organon & Co
Organon & Co (NYSE:OGN) is a healthcare company focused on improving the lives of women worldwide. This organization operates globally, channeling its efforts into developing and bringing to market a broad range of therapies and solutions specifically tailored to address a variety of women's health issues. Beyond its primary mission, Organon is also engaged in expanding its portfolio to include biosimilars, with a keen interest in respiratory, cardiovascular, and dermatological treatments among others. The company is committed to innovation, aiming to fill significant gaps in global healthcare through strategic partnerships, rigorous research, and product development.
Snapshot
Operations
Products and/or services of Organon & Co
- Women's Health Solutions: Focused on therapies and solutions across a woman’s life stages including contraceptive devices, fertility treatments, and menopause management.
- Biosimilars: Developing and commercializing a range of biosimilar medicines with a focus on oncology and autoimmune diseases, aiming to increase patient access to important therapies.
- Established Brands: Marketing a broad portfolio of off-patent medicines that cover a variety of therapeutic areas, ensuring continued patient access to trusted treatments.
- Global Health Initiatives: Engaging in partnerships and programs aimed at improving access to healthcare in low- and middle-income countries, with a focus on reproductive health and family planning.
- Innovative Research in Women’s Health: Investing in research and development to discover and bring to market novel therapies specifically addressing unmet needs in women’s health.
- Pipeline Expansion: Strategically expanding its product pipeline through acquisitions, partnerships, and in-house development with an emphasis on women’s health and biosimilars.
Organon & Co executive team
- Carrie Smith CoxExecutive Chair of the Board
- Joseph T. Morrissey Jr.Chief Executive Officer
- Matthew M. WalshExecutive VP & CFO
- Rachel A. StahlerExecutive VP, Chief Information Officer and Chief Digital & Growth Officer
- Kirke WeaverExecutive VP, General Counsel & Corporate Secretary
- Juan Camilo Arjona FerreiraExecutive VP, Head of Research & Development and Chief Medical Officer
- Jennifer HalchakHead of Investor Relations
- Daniel KarpChief Strategy Officer & Head of Corporate Development
- Aaron FalcioneExecutive VP & Chief Human Resources Officer
- Vittorio NisitaExecutive VP and Head of Enterprise Services & Solutions
Latest news about Organon & Co
Organon announces six-year MIUDELLA Phase 3 data
United StatesOrganon launches denosumab biosimilars in Canada
United StatesOrganon completes licensing deal for 99% effective device
United StatesOrganon and Samsung Bioepis expand biosimilar partnership
United StatesOrganon wins FDA approvals expanding use of Actemra biosimilar Tofidence
United StatesOrganon sales slip 4% as company prepares for $11.7B Sun Pharma merger
United States
Dividend history
Dividends per share paid by Organon & Co, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $0.0600 |
| FY2025 | — | — | — | $0.3400 |
| FY2024 | — | — | — | $1.1200 |
| FY2023 | — | — | — | $1.1200 |
| FY2022 | — | — | — | $1.1200 |
Key financials
Reported results for Organon & Co, in USD.
- Market cap
- 3.6B
- Revenue (TTM)
- 6.1B
- P/E ratio
- 17.7
- EPS (diluted, TTM)
- 0.8
- Dividend yield
- 0.6%
- Profit margin
- 3.5%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 6.2B | 1.3B | 187M | |
| 6.4B | 1.5B | 864M | |
| 6.3B | 1.3B | 1B | |
| 6.2B | 1.7B | 917M |